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Among older mothers, preeclampsia in the first pregnancy was associated with a reduction in maternal breast cancer risk that was
significantly more pronounced in women bearing male than female infants. Androgen concentrations in male, preeclamptic
pregnancies were consistent with the hypothesis that elevated pregnancy androgens might mediate this apparent modifying effect of
fetal gender.
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The reduced risk of breast cancer observed in mothers subsequent
to preeclamptic pregnancies (Polednak and Janerich, 1983;
Thompson et al, 1989; Troisi et al, 1998; Vatten et al, 2002; Innes
and Byers, 2004; Aagaard-Tillery et al, 2006) is curious and the
mechanisms mediating it remain largely unexplored. In their
recent paper on preeclampsia/pregnancy-induced hypertension
and maternal breast cancer risk, Vatten et al (2007) further
characterise this association by offspring’s gender, reporting a risk
reduction with preeclampsia only when the mother carries a male
fetus. The authors conclude that their findings are consistent with
a protective effect originating with exposures incurred during the
pregnancy rather than to an underlying biological trait of the
mother, presumably because such factors would be unrelated to
whether she conceives a female or male child. Previous studies
(Martin et al, 1986; Steier et al, 2002; Troisi et al, 2003; Atamer
et al, 2004) indicate elevations in third trimester circulating
maternal androgen concentrations in preeclampsia compared
with uncomplicated pregnancies. Maternal exposure to elevated
androgen concentrations has been hypothesised to mediate the
protective influence of preeclampsia, perhaps by antagonising
oestrogen’s effects on breast epithelial cells (Innes and Byers, 1999;
Cohn et al, 2001).
We attempted to replicate the findings of Vatten et al of greater
maternal breast cancer protection associated with male pree-
clamptic pregnancies using linked birth and tumour registry data
from a previous population-based study of early-onset breast
cancer (Innes and Byers, 2004). To address the possible role
of androgen concentrations in mediating this apparent risk
reduction, we re-examined data from a longitudinal study of
preeclampsia (Troisi et al, 2003).
MATERIALS AND METHODS
New York state-linked birth and tumour registry data
The study population in this matched case–control study
comprised primiparous women with singleton births who com-
pleted a first pregnancy in New York state (NY) after 1977 (for
detailed description of study population and methods, see Innes
and Byers, 2004). To ensure comparability to Vatten et al’s study,
we included only women with singleton first pregnancies in the
present analysis. Cases were 2489 primiparous women who were
diagnosed with breast cancer in NY between 1979 and 1995 and at
least 1 year after completion of the first pregnancy; age at diagnosis
ranged from 22 to 55 years. Controls were 9967 primiparous
women matched to cases on county of residence and delivery date
and who were not diagnosed with breast or endometrial cancer in
NY. Information on factors characterising each woman’s first
pregnancy was obtained from the birth record of her first-born
infant. The association of preeclampsia and maternal breast cancer
risk was evaluated using conditional logistic regression (Breslow
and Day, 1980).
University of Pittsburgh preeclampsia study
Data were from a longitudinal preeclampsia study conducted at the
University of Pittsburgh (Pittsburgh, PA, USA) that included all
women who attended the Magee Womens Hospital’s obstetric
practice, delivered between February 1994 and May 1998 and
agreed to participate. Eligible for analysis were 86 cases and 86
controls from a previous case-control study of preeclampsia with
singleton pregnancies and without pre-existing diabetes or
hypertension (Troisi et al, 2003). Informed consent for a
questionnaire, interview and blood collection was obtained from
all study participants. Information on the pregnancy was obtained
from medical records. Preeclampsia was defined by explicit criteria
(described in Troisi et al, 2003) based on blood pressure
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ymeasurements, proteinuria and hyperuricemia (Chesley, 1985),
and all diagnoses were reviewed by a jury of clinical experts.
Maternal blood was collected at admission for labor and delivery.
The hormone assays have been described (Troisi et al, 2003).
Briefly, unconjugated concentrations of androstenedione and
testosterone were measured in serum by radioimmunoassay. The
coefficients of variation based on blinded quality control samples
were 10.2% for androstenedione and 9.6% for testosterone.
The hormones were logarithmically transformed to remove
skewness from their distributions. Mean maternal androgen
concentrations were determined for preeclampsia and uncompli-
cated pregnancies by offspring gender using analysis of covariance,
and geometric means and 95% confidence intervals are presented.
Per cent difference was derived from the beta estimate of the case/
control (dichotomous) variable in a generalised linear regression
model with androgens as the dependent variables. Interactions
were tested in linear regression models, with androgens as the
dependent variables and case/control status, offspring gender and
a product term for case/control status and offspring gender as the
independent variables. Statistical significance was defined as
Po0.05 (two-sided).
RESULTS
New York state-linked birth and tumour registry data
Preeclampsia was associated with a modest, non-significant
maternal breast cancer risk reduction overall (maternal age-
adjusted OR¼0.87) that was similar to Vatten et al’s (2007) overall
estimate (RR¼0.86), but a marked and significant risk reduction
among women who delivered their first infant after the age of 30
years (adjusted OR¼0.33) (Table 1). The overall association of
preeclampsia to subsequent breast cancer risk did not differ by
offspring gender (adjusted OR¼0.86 vs 0.90 for women who
delivered a son or a daughter, respectively). However, among the
mothers older than age 30, the risk reduction associated with
preeclampsia was significantly greater for those who carried a male
infant (adjusted OR¼0.18) than female infant (adjusted
OR¼0.52) (P for interaction¼0.01) (Table 1), although risk
reductions were observed for pregnancies involving either gender.
University of Pittsburgh preeclampsia study
While mean androstenedione and testosterone concentrations
were significantly higher in both male and female preeclamptic
compared with uncomplicated pregnancies, absolute concentra-
tions in both preeclamptic and uncomplicated pregnancies were
significantly higher in those involving males than females (Table 2).
Indeed, the concentrations in the uncomplicated male pregnancies
(382 for androstenedione and 166 for testosterone) were similar
to those in preeclamptic female pregnancies (381 and 161,
respectively).
DISCUSSION
The overall estimates for preeclampsia and breast cancer risk in
the present study were similar whether the pregnancy involved a
male or female fetus, consistent with findings from a recent case–
control study conducted in Long Island, NY (Terry et al, 2007).
However, among women who were older at first birth (430 years),
the risk reduction associated with a male fetus was significantly
greater than that associated with a female fetus.
Previous mechanistic investigations regarding the association of
preeclampsia with breast cancer risk have focused on hormones
with an established role in breast carcinogenesis, including
oestrogens (Tamimi et al, 2003; Troisi et al, 2003) and androgens
(Troisi et al, 2003). If the findings of Vatten et al (2007) and what
we observe in the present study among older mothers of male
preeclamptic pregnancies are real, characterising the hormonal
profile of preeclamptic pregnancies by fetal gender and maternal
age may provide additional insight into the mechanisms under-
lying the apparent protective effect of preeclampsia.
In the present study, the highest androgen concentrations were
observed in male, preeclamptic pregnancies. Consistent with these
findings, Steier et al (2002) also showed elevated testosterone
concentrations in male preeclamptic pregnancies relative to both
female preeclamptic pregnancies and uncomplicated pregnancies;
in contrast to our observations, the per cent difference between
testosterone in the preeclamptic and uncomplicated pregnancies
was higher in male- than in female-bearing pregnancies, perhaps
reflecting differences in study sampling times. Collectively, these
data indicate higher absolute (and in Steier et al’s data, higher
relative) androgen concentrations in the maternal circulation of
Table 2 Means for and per cent difference (% diff) with 95% confidence interval (CI) in maternal androgen concentrations between preeclampsia (PE)
cases and uncomplicated (control) pregnancies adjusted for weeks of gestation, by offspring gender
Offspring gender
Female Male
Hormone PE Control % diff
a 95% CI PE Control % diff
a 95% CI p interaction
b
Androstenedione (ngdl
 1) 381 320 27.3 15.6, 40.1 425 382 12.8 4.7, 21.6 0.04
Testosterone (ngdl
 1) 161 139 28.5 16.0, 42.4 180 166 11.4 2.5, 21.2 0.03
aPer cent difference (% diff) derives from the beta estimate of the case/control variable in a generalised linear regression model, with logarithm-transformed values for the
maternal androgens as the dependent variables. Interactions were tested in a linear regression model, with logarithm-transformed androgens as the dependent variables and
case/control status, offspring sex and an interaction term for case/control status   offspring sex as the independent variables.
bp interaction refers to the comparison of per cent
difference in each androgen between PE and control pregnancies by offspring gender.
Table 1 Odds ratios (OR) and 95% confidence intervals (CI) for
preeclampsia (PE) in the first pregnancy and subsequent maternal breast
cancer risk among women 22–55 years of age, New York state, USA
No. of cases/controls with PE OR
a 95% CI
All births 95/386 0.87 (0.67–1.13)
Male infant 45/208 0.86 (0.60–1.22)
Female infant 50/178 0.90 (0.64–1.27)
p interaction 0.86
Maternal age 430 46/79 0.33 (0.16–0.65)
Male infant 22/42 0.18 (0.04–0.87)
Female infant 24/37 0.52 (0.13–2.0)
p interaction 0.01
aOdds ratio adjusted for maternal age.
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ypreeclamptic pregnancies involving a male fetus compared with
those involving a female fetus. This suggests that the observed
protective effect of preeclampsia on breast cancer risk may in part
rely on meeting or exceeding a specific threshold of exposure to
endogenous androgens. Because uncomplicated male pregnancies
have higher androgen concentrations than uncomplicated female
pregnancies, one might expect offspring gender to be associated
with maternal breast cancer risk even in normal pregnancy.
However, previous studies have not consistently demonstrated
such an association (Olsen and Storm, 1998; Troisi et al, 1998;
Hsieh et al, 1999; Cnattingius et al, 2005); thus, if protection is
associated with absolute androgen concentration, the threshold for
this effect must be above the levels characterising uncomplicated
male pregnancies. Whether this is biologically plausible is unclear.
Preeclamptic pregnancies that involve male offspring may also
differ in other biological factors, such as human chorionic
gonadotropin (hCG) (Steier et al, 2002), which has been shown
to be higher in male preeclamptic pregnancies than in female
preeclamptic pregnancies or in uncomplicated pregnancies invol-
ving either offspring gender. Human chorionic gonadotropin has
been linked to reduced breast cancer risk in human populations,
and has been repeatedly shown to promote mammary gland
differentiation and inhibit neoplastic changes in animal models
(Innes and Byers, 1999; Janssens et al, 2007). The significantly
greater increases in hCG associated with male preeclamptic
pregnancies may also in part account for the higher androgen
concentrations observed in both our data and that of Steier et al
(2002). Other biological mechanisms have also been proposed to
explain the observed protective effect of preeclampsia, including
immunological factors (Polednak and Janerich, 1983) and altera-
tions in IGF-1 and other compounds linked to breast cancer
initiation and promotion (Innes and Byers, 1999, 2004). More
recent speculation has focused on the antiangiogenic profile of
women who develop pregnancy-induced hypertension (Aagaard-
Tillery et al, 2006).
The possibility that preeclampsia affords greater protection for
maternal breast cancer in pregnancies involving male fetuses merits
replication in other large population-based studies. If confirmed,
evaluation by offspring gender of the biomarkers mentioned above
as well as others that are known to be altered in preeclamptic
pregnancies may further our understanding of the apparent
protective influence of preeclampsia on breast carcinogenesis.
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